innovation for industry
Articles ＆ files | Focus | Article
Peps enables large scale clinical testing using MS-based proteomics, and the discovery of new biomarkers.
PepS is a highly reliable and robust microfluidic device that rapidly processes whole blood samples at the patient's bedside, delivering deferred downstream MS-based proteomics analyses.
The first prototype was released in 2019. Researchers are currently discussing further collaborations with industrials working within the proteomic environment.
- ac-2020-02270g.R3. PepS: an innovative microfluidic device for bedside whole blood processing before plasma proteomics analyses.
Gilquin, Benoit; Cubizolles, Myriam; Den Dulk, Remco; Revol-Cavalier, Frederic; Alessio, Manuel; Goujon, Charles-Elie; Echampard, Camille; Arrizabalaga, Gorka; Adrait, Annie; Louwagie, Mathilde; Laurent, Patricia; Navarro, Fabrice; Couté, Yohann; Cosnier, Marie-Line; Brun, Virginie Manuscript
Conference Poster : SMAP 2019,Lab-On-Chip 2019 et μTAS 2019
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.